Le Lézard
Classified in: Health, Science and technology
Subject: FDA

Shingrix with QS-21 Stimulon® Receives Positive Recommendation from CDC's Advisory Committee on Immunization Practices as Preferred Vaccine for Prevention of Shingles


LEXINGTON, Mass., Oct. 25, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor of three recommendations for the use of Shingrix (Zoster Vaccine Recombinant, Adjuvanted) containing QS-21 Stimulon® for the prevention of shingles (herpes zoster):

Agenus Logo

"The Advisory Committee's vote to recommend Shingrix enhanced with QS-21 Stimulon on three different counts further confirms our belief in the vaccine's efficacy and its potential to extend immunization for up to 62 million adults in the United States," remarked Garo Armen, Ph.D., Chairman and CEO, Agenus. "Today's vote confirms the importance of ensuring that millions of at-risk adults are protected against shingles with Shingrix."

QS-21 Stimulon is an immune-potent adjuvant designed to boost the immune system by helping the body generate antibodies and T cells that guard against infection. The addition of QS-21 Stimulon enhances the immunogenicity of Shingrix by boosting immune response, which is critically important for older adults, the population most vulnerable to shingles and the painful and often debilitating consequences of the virus.

Shingrix was approved by the US Food and Drug Administration (FDA) on October 20, 2017 for use in adults aged 50 years and older. Data from studies of people vaccinated with Shingrix, who were previously vaccinated with Zostavax, have been presented previously to the ACIP and have been published in peer-reviewed journals, but have not yet been reviewed by the FDA.[i],[ii] 

The most common side effects of Shingrix are pain, redness, and swelling at the injection site, muscle pain, tiredness, headache, shivering, fever, and upset stomach, which are related to the immune system responding to the vaccine. Based on available data, the majority of reactions to the vaccine were transient and mild to moderate in intensity, lasting less than three days.

Shingles is a major public health issue in the US, impacting as many as 1 in 3 older adults over the age of 50 years. Shingles is caused by a virus called varicella zoster, which is also known as the chicken pox virus. Nearly all older adults have the varicella zoster virus dormant in their nervous system waiting to reactivate with advancing age and weakened immune systems.

The ACIP recommendations will be forwarded to the director of the CDC and the US Department of Health and Human Services for review and approval. Once approved, the final recommendations will be published in a future Morbidity and Mortality Weekly Report (MMWR).

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing a number of combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.

Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the potential for Shingrix to extend immunization for up to 62 million adults in the United States. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact:
Agenus Inc. 
Jennifer Buell, PhD
781-674-4420 
Jennifer.Buell@agenusbio.com

i https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2017-06/zoster-03-colindres.pdf

ii https://academic.oup.com/jid/article/doi/10.1093/infdis/jix482/4209275/Immunogenicity-and-Safety-of-the-HZ-su-Adjuvanted

SOURCE Agenus Inc.


These press releases may also interest you

20 mar 2019
OnlineMasters.com, a trusted source for unbiased college rankings and higher education planning, announced the release of their Best Online Master's in Social Studies Programs for 2019. The research identifies the top programs in the nation based on...

20 mar 2019
J55 Capital Corp. ("J55" or the "Company") is pleased to announce that Aquilini GameCo Inc. (the "Target") has raised $25,000,200 pursuant to a private placement offering (the "Target Financing").  Canaccord Genuity Corp. (the "Agent") acted as the...

20 mar 2019
Today, leaders representing G20 nations convened at the second annual Alzheimer's Scientific Roundtable to call on Japanese Prime Minister Shinzo Abe to act decisively and make the global Alzheimer's crisis a primary focus of this year's G20 summit...

20 mar 2019
Internet of Things (IoT) in Healthcare Market Size, Share & Trends Analysis Report By End Use, By Component, By Connectivity Technology (Cellular, Wi-Fi, Satellite), By Application, And Segment Forecasts, 2018 - 2025Read the full report:...

20 mar 2019
Today at Semicon China 2019, Thermo Fisher Scientific unveiled its latest and most advanced focused ion beam scanning electron microscope (FIB-SEM) for nanometer scale materials characterization and analysis, the Thermo Scientific Helios 5 DualBeam...

20 mar 2019
Magnitude Software, Inc., a leader in delivering unified application data management to global organizations, today announced that Forrester Research, Inc., a leading independent technology and market research company, has positioned the Company's...



News published on 25 october 2017 at 16:24 and distributed by: